The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...

Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast ...

AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...

Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...

The global breast cancer drugs market size was valued at USD 34.25 billion in 2024 and is projected to reach from USD 37.30 ...

Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca (NASDAQ:AZN), highlighted the potential for Enhertu to become the first HER2-directed treatment for this ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...